Innovative iPSC Platform for ALS Therapeutic Screening and Research
Advancing Drug Discovery with Human iPSC-Derived 3D Neurospheres
.png)
User guide: Ncyte® Motor Neurons
User guide: Ncyte® Cholinergic Neurons
User guide: Ncyte® Excitatory Neurons
User guide: Ncyte® GABAergic Neurons.
Engineered heart tissues for cardiac safety assessment
NHP iPSC cardiomyocytes for translational cardiac safety
User guide: iPSC- Alveolar Type II Cells
User guide: NHP- C Cardiac Fibroblasts
Accelerate Neuroscience Drug Discovery withAssay-Ready Human iPSC-Derived Neurons
.png)
Using NHP iPSC Models to Investigate Translational Differences
Ncyte® Heart in a Box™: Scalable 3D Cardiac Models for Drug Discovery
Building AAV Screening Workflows That Translate to GMP
.png)
iPSC Models and Immunogenicity for Antibodies & Bioconjugates
.png)
Robust Drug Screening with Human iPSC-Derived Models
.png)
Designing cardiac assays for multi-year discovery and safety pipelines
Beyond Binding: iPSC-Based Functional Safety Screening in Oncology
Advancing Gene Therapy Potency Testing with iPSC-Based Systems
Revolutionizing Cardiac Safety Assessment with NHP Cardiomyocytes
.png)
Preclinical Toxicology for IO Biologics
-1.png)
Press release: Ncardia and Cellistic appoint Jason Conner as new CEO
Early Safety Assessment and Human-Relevant Models in Drug Development
Ncardia and LUMC Develop Automated Human Cardiac Microtissue Platform
Scaling Human Biology: Mariana Argenziano on iPSC Manufacturing
.svg)
Human-Relevant Drug Discovery: A Conversation With Shushant Jain
.png)
Human-Relevant Immuno-Oncology Models: Interview with Sanne Holt
Human-Relevant Drug Discovery: Advancing Predictive Science
Ncardia Launches NHP iPSC-Derived Cardiomyocytes for Cardiac Safety
FDA's Shift Beyond Animal Testing: Ncardia's iPSC Models